BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33865804)

  • 1. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.
    Hsu JW; Farhadfar N; Murthy H; Logan BR; Bo-Subait S; Frey N; Goldstein SC; Horowitz MM; Lazarus H; Schwanke JD; Shah NN; Spellman SR; Switzer GE; Devine SM; Shaw BE; Wingard JR
    Transplant Cell Ther; 2021 Jun; 27(6):507-516. PubMed ID: 33865804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
    Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
    Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program.
    Kanda Y; Inoue M; Uchida N; Onishi Y; Kamata R; Kotaki M; Kobayashi R; Tanaka J; Fukuda T; Fujii N; Miyamura K; Mori SI; Mori Y; Morishima Y; Yabe H; Kodera Y
    Transplant Cell Ther; 2021 Aug; 27(8):664.e1-664.e6. PubMed ID: 33964514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryopreservation of Growth Factor-Mobilized Peripheral Blood Stem Cells Does Not Compromise Major Outcomes after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.
    Connelly-Smith L; Gooley T; Roberts L; Mielcarek M; Linenberger M; Petersdorf E; Sandmaier BM; Milano F
    Transplant Cell Ther; 2023 Nov; 29(11):700.e1-700.e8. PubMed ID: 37659695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report.
    Bankova AK; Caveney J; Yao B; Ramos TL; Bögeholz J; Heydari K; Diaz N; Jackson ML; Lowsky R; Brown JW; Johnston L; Rezvani AR; Frank MJ; Muffly L; Weng WK; Sidana S; Negrin RS; Miklos DB; Shiraz P; Meyer EH; Shizuru JA; Arai S
    Transplant Cell Ther; 2022 Apr; 28(4):215.e1-215.e10. PubMed ID: 35042013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantation in the Era of the COVID-19 Pandemic: An Update from the Japan Marrow Donor Program.
    Kanda Y; Doki N; Kojima M; Kako S; Inoue M; Uchida N; Onishi Y; Kamata R; Kotaki M; Kobayashi R; Tanaka J; Fukuda T; Fujii N; Miyamura K; Mori SI; Mori Y; Morishima Y; Yabe H; Atsuta Y; Kodera Y
    Transplant Cell Ther; 2022 Oct; 28(10):677.e1-677.e6. PubMed ID: 35803526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryopreservation of Allogeneic Hematopoietic Cell Products During COVID-19 Pandemic: Graft Characterization and Engraftment Outcomes.
    Keyzner A; Azzi J; Jakubowski R; Sinitsyn Y; Tindle S; Shpontak S; Kwon D; Isola L; Iancu-Rubin C
    Transplant Proc; 2023 Oct; 55(8):1799-1809. PubMed ID: 37210273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic.
    Devine SM; Bo-Subait S; Kuxhausen M; Spellman SR; Bupp C; Ahn KW; Stefanski HE; Auletta JJ; Logan BR; Shaw BE
    Blood Adv; 2023 Oct; 7(19):5982-5993. PubMed ID: 37036959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience.
    Guo M; Liu J; Clark P; Ahmad S; Patel R; Varela JC; Mori S
    Int J Hematol; 2023 Mar; 117(3):428-437. PubMed ID: 36378406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution.
    Maurer K; Kim HT; Kuczmarski TM; Garrity HM; Weber A; Reynolds CG; Liney D; Cutler C; Antin JH; Koreth J; Ritz J; Shapiro RM; Romee R; Wu CJ; Soiffer RJ; Nikiforow S; Ho VT; Gooptu M
    Blood Adv; 2021 Dec; 5(23):5140-5149. PubMed ID: 34581754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
    Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
    Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Shimoni A; Niederwieser D; Mufti GJ; Zander AR; Arnold R; Greinix H; Cornelissen JJ; Jackson GH; Craddock C; Bunjes DW; Ganser A; Russell NH; Kyrcz-Krzemien S; Rocha V; Mohty M
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1422-9. PubMed ID: 22446014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients.
    Jo T; Arai Y; Kondo T; Mizuno S; Hirabayashi S; Inamoto Y; Doki N; Fukuda T; Ozawa Y; Katayama Y; Kanda Y; Fukushima K; Matsuoka KI; Takada S; Sawa M; Ashida T; Onizuka M; Ichinohe T; Atsuta Y; Kanda J; Yanada M
    Cytotherapy; 2022 Oct; 24(10):1013-1025. PubMed ID: 35729020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?
    Fernandez-Sojo J; Azqueta C; Valdivia E; Martorell L; Medina-Boronat L; Martínez-Llonch N; Torrents S; Codinach M; Canals C; Elorza I; Parody R; Martino R; Trabazo M; Díaz de Heredia C; Ferra C; Valcárcel D; Linares M; Ancochea Á; García-Rey E; García-Muñoz N; Medina L; Castillo N; Carreras E; Villa J; Querol S
    Bone Marrow Transplant; 2021 Oct; 56(10):2489-2496. PubMed ID: 34127808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.
    Alousi A; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Pidala J; Anderlini P; Boyiadzis M; Bredeson CN; Cahn JY; Cairo MS; Gadalla SM; Hashmi SK; Gale RP; Kanda J; Kamble RT; Kharfan-Dabaja MA; Litzow MR; Ringden O; Saad AA; Schultz KR; Verdonck LF; Waller EK; Yared JA; Holtan SG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):270-278. PubMed ID: 30292009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3
    Lum SH; James B; Ottaviano G; Ewins AM; Patrick K; Ali S; Carpenter B; Silva J; Tewari S; Furness C; Thomas A; Shenton G; Bonney D; Moppett J; Hambleton S; Gennery AR; Amrolia P; Gibson B; Hough R; Rao K; Slatter M; Wynn R
    Transplant Cell Ther; 2024 Mar; 30(3):314.e1-314.e12. PubMed ID: 38103787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option.
    Alotaibi AS; Prem S; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
    Am J Hematol; 2021 Feb; 96(2):179-187. PubMed ID: 33108034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.